OvaScience Inc. (NASDAQ:OVAS) dropped 3.4% during trading on Tuesday . The stock traded as low as $6.10 and last traded at $6.22, with a volume of 98,742 shares. The stock had previously closed at $6.44.

OVAS has been the subject of a number of analyst reports. Oppenheimer Holdings Inc. reiterated a “hold” rating on shares of OvaScience in a research note on Monday, April 25th. Credit Suisse Group AG reiterated a “sell” rating on shares of OvaScience in a research note on Tuesday, July 12th. Zacks Investment Research upgraded OvaScience from a “hold” rating to a “buy” rating and set a $7.00 price target for the company in a research note on Wednesday, August 10th. JMP Securities reiterated a “neutral” rating on shares of OvaScience in a research note on Wednesday, August 10th. Finally, JPMorgan Chase & Co. cut their price target on OvaScience from $9.00 to $8.00 and set a “neutral” rating for the company in a research note on Friday, August 5th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the stock. OvaScience presently has an average rating of “Hold” and an average price target of $10.98.

The company’s 50-day moving average is $5.54 and its 200-day moving average is $7.06. The company’s market capitalization is $216.57 million.

OvaScience (NASDAQ:OVAS) last posted its quarterly earnings data on Thursday, August 4th. The company reported ($0.62) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.78) by $0.16. The company had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.21 million. During the same quarter in the previous year, the firm posted ($0.64) earnings per share. The company’s quarterly revenue was up 530.0% on a year-over-year basis. On average, analysts forecast that OvaScience Inc. will post ($2.66) earnings per share for the current fiscal year.

In other OvaScience news, CEO Michelle Dipp bought 425,000 shares of the firm’s stock in a transaction that occurred on Wednesday, June 1st. The stock was bought at an average cost of $7.00 per share, for a total transaction of $2,975,000.00. Following the completion of the transaction, the chief executive officer now directly owns 971,921 shares of the company’s stock, valued at approximately $6,803,447. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

OvaScience, Inc is a global fertility company. The Company is focused on the discovery, development and commercialization of fertility treatment options for women. The Company’s portfolio of fertility treatment options uses its technology, including methods to identify and isolate Egg precursor (EggPC) cells from a patient’s own ovarian tissue.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.